In preclinical models, XN has exhibited the ability to improve insulin sensitivity, regulate blood glucose levels, and ameliorate lipid profiles, positioning it as a potential therapeutic for type 2 diabetes and metabolic syndrome. This evidence concerns the gene INS and type 2 diabetes mellitus.